Mammoth Biosciences has raised $45 million in an oversubscribed Series B financing with the goal of expanding beyond CRISPR-based disease detection—including a collaboration targeting 2019-nCoV coronavirus—towards offerings that apply the company’s platform to gene editing and next-generation therapeutics . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge